id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-V-7020-0002,FDA,FDA-2017-V-7020,Acknowledgment Letter from FDA DDM to W6 Restaurant Group LTD,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T16:38:57Z,,0,0,0900006482d83ab8
FDA-2017-H-6960-0001,FDA,FDA-2017-H-6960,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T18:59:43Z,,0,0,0900006482d84c25
FDA-2017-H-6973-0001,FDA,FDA-2017-H-6973,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T19:30:07Z,,0,0,0900006482d84ca5
FDA-2017-V-7020-0001,FDA,FDA-2017-V-7020,Variance Application from W6 Restaurant Group LTD,Other,Application for Variance (VAR),2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T16:38:51Z,,0,0,0900006482d83ab6
FDA-2017-P-7031-0002,FDA,FDA-2017-P-7031,"Acknowledgment Letter from FDA DDM to JRRapoza Associates, Inc",Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T17:34:05Z,,0,0,0900006482d8388f
FDA-2017-P-7032-0001,FDA,FDA-2017-P-7032,Citizen Petition from Jubilant Generics Limited,Other,Citizen Petition,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-06-28T03:59:59Z,2018-01-02T16:48:06Z,,0,0,0900006482d843bf
FDA-2017-V-7023-0001,FDA,FDA-2017-V-7023,Variance Application from Platinum AVL,Other,Application for Variance (VAR),2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T16:37:20Z,,0,0,0900006482d83c59
FDA-1977-N-0025-0007,FDA,FDA-1977-N-0025,Supplement from Wyeth Consumer Healthcare,Other,Supplement (SUP),2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2019-02-01T15:40:00Z,,0,0,09000064805da2f9
FDA-2017-H-6986-0001,FDA,FDA-2017-H-6986,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T20:05:43Z,,0,0,0900006482d85162
FDA-2017-V-7021-0002,FDA,FDA-2017-V-7021,Acknowledgment Letter from FDA DDM to Trio Nightclub,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T16:41:48Z,,0,0,0900006482d83abe
FDA-2014-P-0646-0011,FDA,FDA-2014-P-0646,Letter from Kamat Pharmatech to FDA DDM,Other,Letter(s),2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T16:42:48Z,,0,0,0900006482d8388b
FDA-2017-P-7032-0002,FDA,FDA-2017-P-7032,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2018-01-02T16:48:30Z,,0,0,0900006482d843c1
FDA-2017-H-6948-0001,FDA,FDA-2017-H-6948,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T18:48:22Z,,0,0,0900006482d84e08
FDA-2017-P-7033-0001,FDA,FDA-2017-P-7033,Citizen Petition from Jubliant Generics Limited,Other,Citizen Petition,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-06-28T03:59:59Z,2018-01-02T16:50:17Z,,0,0,0900006482d84d79
FDA-2017-H-6958-0001,FDA,FDA-2017-H-6958,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T18:54:54Z,,0,0,0900006482d84e3e
FDA-2017-H-6952-0001,FDA,FDA-2017-H-6952,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T18:47:45Z,,0,0,0900006482d84e02
FDA-2017-D-6530-0002,FDA,FDA-2017-D-6530,Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-03-30T03:59:59Z,2024-11-07T01:15:37Z,,1,0,0900006482d7eb25
FDA-2017-D-6564-0002,FDA,FDA-2017-D-6564,"Best Practices for Communication Between IND Sponsors and FDA
During Drug Development Guidance for Industry and Review Staff",Other,Guidance,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2024-11-07T01:15:37Z,,1,0,0900006482d7eb23
FDA-2017-P-7033-0002,FDA,FDA-2017-P-7033,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2018-01-02T16:50:45Z,,0,0,0900006482d84da4
FDA-2017-P-7034-0001,FDA,FDA-2017-P-7034,Citizen Petition from Jubilant Generics Limited,Other,Citizen Petition,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-06-28T03:59:59Z,2018-01-02T16:52:40Z,,0,0,0900006482d84d2a
FDA-2017-P-7031-0001,FDA,FDA-2017-P-7031,"Citizen Petition from JRRapoza Associates, Inc",Other,Citizen Petition,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-06-28T03:59:59Z,2017-12-29T17:33:49Z,,0,0,0900006482d8388d
FDA-2016-N-0832-0057,FDA,FDA-2016-N-0832,Letter from Phibro Animal Health Corporation,Other,Letter(s),2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T15:57:53Z,,0,0,0900006482d83a18
FDA-2017-V-7023-0002,FDA,FDA-2017-V-7023,Acknowledgement Letter from FDA DDM to Platinum AVL,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T16:37:25Z,,0,0,0900006482d83c5c
FDA-2017-V-7028-0002,FDA,FDA-2017-V-7028,Acknowledgement Letter from FDA DDM to Richard Nguyen,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T18:19:48Z,,0,0,0900006482d84abf
FDA-2017-H-6963-0001,FDA,FDA-2017-H-6963,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T19:24:17Z,,0,0,0900006482d84efa
FDA-2017-P-7034-0002,FDA,FDA-2017-P-7034,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited,Other,Acknowledgement Letter/Receipt,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2018-01-02T16:53:05Z,,0,0,0900006482d84d2c
FDA-2017-H-6953-0001,FDA,FDA-2017-H-6953,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T18:45:41Z,,0,0,0900006482d84e38
FDA-2017-V-7021-0001,FDA,FDA-2017-V-7021,Variance Application from Trio Nightclub,Other,Application for Variance (VAR),2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T16:41:43Z,,0,0,0900006482d83abc
FDA-2017-V-7028-0001,FDA,FDA-2017-V-7028,Variance Application from RICHARD NGUYEN,Other,Application for Variance (VAR),2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T18:19:42Z,,0,0,0900006482d837cd
FDA-2017-H-6972-0001,FDA,FDA-2017-H-6972,Complaint,Other,Complaint,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T19:11:59Z,,0,0,0900006482d84ef4
FDA-1980-N-0038-0138,FDA,FDA-1980-N-0038,"Certain Topical Anti-Infective Drug Products; Vioform-Hydrocortisone (Iodochlorhydroxyquin and Hydrocortisone) Request of CIBA-GEIGY Corporation for Hearing Vol I re: Supplement from CIBA-GEIGY (Wald, Harkrader & Ross) (Vol 1 of 3)",Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2017-12-28T18:11:59Z,,0,0,09000064805b963e
FDA-2017-P-4039-0003,FDA,FDA-2017-P-4039,Interim Response Letter from FDA CDER to Center for Lawful Access and Abuse Deterrence,Other,Letter(s),2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T21:28:04Z,,0,0,0900006482d7f298
FDA-2015-V-0429-0003,FDA,FDA-2015-V-0429,"Approval Letter from FDA CDRH to Power Technology, Inc.",Other,Approval for Variance (VRA),2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T15:21:49Z,,0,0,0900006482d7b398
FDA-2017-H-6956-0001,FDA,FDA-2017-H-6956,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T15:55:12Z,,0,0,0900006482d7b912
FDA-2017-H-6957-0001,FDA,FDA-2017-H-6957,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T18:31:50Z,,0,0,0900006482d7c0f5
FDA-2017-H-6954-0001,FDA,FDA-2017-H-6954,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T15:25:41Z,,0,0,0900006482d7b39a
FDA-2017-H-6962-0001,FDA,FDA-2017-H-6962,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T19:21:49Z,,0,0,0900006482d7db54
FDA-2005-D-0140-0010,FDA,FDA-2005-D-0140,"Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry:  Guidance for Industry",Other,Guidance,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2024-11-07T01:15:24Z,,1,0,0900006482d7ee3c
FDA-2017-H-6965-0001,FDA,FDA-2017-H-6965,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T19:25:13Z,,0,0,0900006482d7e13f
FDA-1980-N-0038-0156,FDA,FDA-1980-N-0038,"Request for Hearing from Clay-Park Labs, Inc.",Other,Request for Hearing,2017-12-28T05:00:00Z,2017,12,,,2017-12-28T19:23:17Z,,0,0,09000064805b964a
FDA-1980-N-0038-0141,FDA,FDA-1980-N-0038,"Letter from Miles Laboratories, Inc. to FDA/DDM",Other,Letter(s),2017-12-28T05:00:00Z,2017,12,,,2017-12-28T18:13:51Z,,0,0,09000064805b963f
FDA-1980-N-0038-0153,FDA,FDA-1980-N-0038,"Answer Letter from Arthur Hull Hayes, Jr. to American Academy of Dermatology, Inc.",Other,Answer,2017-12-28T05:00:00Z,2017,12,,,2017-12-28T19:21:20Z,,0,0,09000064805b9647
FDA-1980-N-0038-0155,FDA,FDA-1980-N-0038,"Letter from Linda M. Quinones to American Academy of Dermatology, Inc.",Other,Letter(s),2017-12-28T05:00:00Z,2017,12,,,2017-12-28T19:22:12Z,,0,0,09000064805b9649
FDA-1980-N-0038-0148,FDA,FDA-1980-N-0038,Supplement from Burroughs Wellcome Co. (Vol. 1 of 5),Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2020-01-31T06:55:40Z,,0,0,09000064805b9646
FDA-1980-N-0038-0133,FDA,FDA-1980-N-0038,Supplement from Merck Sharp & Dohme Research Labs (Vol. 1 of 4),Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2017-12-28T18:05:18Z,,0,0,09000064805b963c
FDA-1980-N-0038-0142,FDA,FDA-1980-N-0038,"Withdrawal Letter from Miles Laboratories, Inc.",Other,Withdrawal,2017-12-28T05:00:00Z,2017,12,,,2017-12-28T18:19:41Z,,0,0,09000064805b9640
FDA-2017-H-6964-0001,FDA,FDA-2017-H-6964,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T19:23:34Z,,0,0,0900006482d7db87
FDA-2017-V-6985-0001,FDA,FDA-2017-V-6985,Variance Application from Aka Booking Agency,Other,Application for Variance (VAR),2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T15:15:52Z,,0,0,0900006482d73063
FDA-2017-H-6966-0001,FDA,FDA-2017-H-6966,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T19:32:32Z,,0,0,0900006482d7e147
FDA-1980-N-0038-0147,FDA,FDA-1980-N-0038,"Supplement from Mayrand, Inc. Pharmaceuticals",Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2020-01-31T06:55:39Z,,0,0,09000064805b9645
FDA-1980-N-0038-0145,FDA,FDA-1980-N-0038,"Supplement from UAD Laboratories, Inc.",Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2020-01-31T06:55:40Z,,0,0,09000064805b9643
FDA-1980-N-0038-0119,FDA,FDA-1980-N-0038,Supplement from National Pharmaceutical Alliance,Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2017-12-28T18:02:14Z,,0,0,09000064805b962f
FDA-1980-N-0038-0143,FDA,FDA-1980-N-0038,Correction from the Lemmon Company,Other,Correction(s),2017-12-28T05:00:00Z,2017,12,,,2018-01-02T20:45:08Z,,0,0,09000064805b9641
FDA-1980-N-0038-0137,FDA,FDA-1980-N-0038,"The Proposal to Withdraw the New Drug Application for Terra-Cortril Topical Ointment (NDA 61-011, Section 446.567(a)) - Submission of Data for Terra-Cortril Topical Ointment re Supplement from Pfizer Inc.",Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2017-12-28T18:11:19Z,,0,0,09000064805b963d
FDA-1980-N-0038-0144,FDA,FDA-1980-N-0038,"Supplement from Marnel Pharmaceuticals, Inc.",Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2020-01-31T07:27:06Z,,0,0,09000064805b9642
FDA-1980-N-0038-0146,FDA,FDA-1980-N-0038,"Supplement from Dermik Laboratories, Inc.",Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2020-01-31T06:55:40Z,,0,0,09000064805b9644
FDA-1980-N-0038-0154,FDA,FDA-1980-N-0038,"Amendment from BYK-Gulden, Inc. (Covington & Burling)",Other,Amendment,2017-12-28T05:00:00Z,2017,12,,,2017-12-28T19:21:07Z,,0,0,09000064805b9648
FDA-2017-V-6985-0002,FDA,FDA-2017-V-6985,Acknowledgement Letter from FDA DDM to AKA Booking Agency,Other,Acknowledgement Letter/Receipt,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T15:15:57Z,,0,0,0900006482d73066
FDA-2017-H-6951-0001,FDA,FDA-2017-H-6951,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T18:19:30Z,,0,0,0900006482d7c150
FDA-2017-V-4971-0003,FDA,FDA-2017-V-4971,Response Letter from FDA CDRH to Charles Gardner,Other,Agency Response,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T18:12:31Z,,0,0,0900006482d7c89e
FDA-1980-N-0038-0157,FDA,FDA-1980-N-0038,"Supplement from Syntex Laboratories (Kleinfeld, Kaplan and Becker)",Other,Supplement (SUP),2017-12-28T05:00:00Z,2017,12,,,2017-12-28T19:24:45Z,,0,0,09000064805b964b
FDA-2014-V-2139-0003,FDA,FDA-2014-V-2139,Approval Letter from FDA DDM to Laserdock Limited,Other,Approval for Variance (VRA),2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T18:20:46Z,,0,0,0900006482d7c8a0
FDA-2017-H-6961-0001,FDA,FDA-2017-H-6961,Complaint,Other,Complaint,2017-12-28T05:00:00Z,2017,12,2017-12-28T05:00:00Z,,2017-12-28T18:33:17Z,,0,0,0900006482d7c7a2
FDA-2017-D-6784-0002,FDA,FDA-2017-D-6784,"Implementation of Pathogen Reduction Technology in the Manufacture of Blood Components in Blood Establishments: Questions and Answers
Draft Guidance for Industry",Other,Guidance,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,2018-03-28T03:59:59Z,2024-11-07T01:15:33Z,,1,0,0900006482d77d2d
FDA-1980-N-0038-0117,FDA,FDA-1980-N-0038,Supplement from E. R. Squibbs & Sons (Vol. 1 of 2),Other,Supplement (SUP),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T15:18:57Z,,0,0,09000064805b962e
FDA-2017-H-6946-0001,FDA,FDA-2017-H-6946,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T15:59:25Z,,0,0,0900006482d76e76
FDA-2017-V-4514-0003,FDA,FDA-2017-V-4514,"Approval Letter from FDA CDRH to Princeton Lightwave, Inc",Other,Approval for Variance (VRA),2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T21:32:29Z,,0,0,0900006482d78a75
FDA-2017-H-6937-0001,FDA,FDA-2017-H-6937,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T15:56:30Z,,0,0,0900006482d77270
FDA-2017-H-6945-0001,FDA,FDA-2017-H-6945,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T15:21:10Z,,0,0,0900006482d76d5e
FDA-2017-H-6913-0001,FDA,FDA-2017-H-6913,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T19:17:29Z,,0,0,0900006482d782be
FDA-2017-P-5435-0003,FDA,FDA-2017-P-5435,"Withdrawal from Hyman, Phelps & McNamara PC",Other,Withdrawal,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T21:01:16Z,,0,0,0900006482d72ce0
FDA-2017-H-6932-0001,FDA,FDA-2017-H-6932,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T12:48:34Z,,0,0,0900006482d748e1
FDA-2017-H-6938-0001,FDA,FDA-2017-H-6938,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T13:29:26Z,,0,0,0900006482d761f0
FDA-2017-H-6926-0001,FDA,FDA-2017-H-6926,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T13:32:34Z,,0,0,0900006482d74189
FDA-1980-N-0038-0113,FDA,FDA-1980-N-0038,"Supplement from Syntex Laboratories, Inc. (Vol. 1 of 3)",Other,Supplement (SUP),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T15:19:54Z,,0,0,09000064805b962c
FDA-1980-N-0038-0103,FDA,FDA-1980-N-0038,"Supplement from Byk-Gilden, Inc. (Vol. 1 of 2)",Other,Supplement (SUP),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T15:20:26Z,,0,0,09000064805b9629
FDA-1980-N-0038-0114,FDA,FDA-1980-N-0038,Supplement from Burroughs Wellcome Co. ( Vol. 1 of 3),Other,Supplement (SUP),2017-12-27T05:00:00Z,2017,12,,,2020-01-31T06:55:41Z,,0,0,09000064805b962d
FDA-2017-H-6929-0001,FDA,FDA-2017-H-6929,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T12:31:38Z,,0,0,0900006482d74016
FDA-2017-H-6950-0001,FDA,FDA-2017-H-6950,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T15:46:57Z,,0,0,0900006482d76cc4
FDA-1980-N-0038-0102,FDA,FDA-1980-N-0038,Letter from the Upjohn Company to FDA/DDM,Other,Letter(s),2017-12-27T05:00:00Z,2017,12,,,2017-12-28T17:51:24Z,,0,0,09000064805b9627
FDA-2017-H-6916-0001,FDA,FDA-2017-H-6916,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T19:42:04Z,,0,0,0900006482d78196
FDA-2017-H-6935-0001,FDA,FDA-2017-H-6935,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T15:51:02Z,,0,0,0900006482d76cf7
FDA-2017-H-6944-0001,FDA,FDA-2017-H-6944,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T14:39:57Z,,0,0,0900006482d75e9f
FDA-2017-H-6936-0001,FDA,FDA-2017-H-6936,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T15:53:33Z,,0,0,0900006482d76d56
FDA-2017-H-6941-0001,FDA,FDA-2017-H-6941,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T14:12:22Z,,0,0,0900006482d75d94
FDA-2017-H-6930-0001,FDA,FDA-2017-H-6930,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T12:39:22Z,,0,0,0900006482d748db
FDA-2017-H-6920-0001,FDA,FDA-2017-H-6920,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T19:46:59Z,,0,0,0900006482d77e08
FDA-1980-N-0038-0105,FDA,FDA-1980-N-0038,"Request of Dermik Laboratories, Inc., for Withdrawal of Notice of Opportunity for Hearing and Submission in Support of Request for Hearing (Vol. 1 of 4)",Other,Supplement (SUP),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T14:18:28Z,,0,0,09000064805b962a
FDA-2017-H-6942-0001,FDA,FDA-2017-H-6942,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T14:22:37Z,,0,0,0900006482d76bea
FDA-2017-H-6949-0001,FDA,FDA-2017-H-6949,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T16:35:58Z,,0,0,0900006482d76e04
FDA-2017-H-6947-0001,FDA,FDA-2017-H-6947,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T16:34:07Z,,0,0,0900006482d76d64
FDA-1980-N-0038-0109,FDA,FDA-1980-N-0038,Supplement from Lilly Research Laboratories (Vol. 1 of 2),Other,Supplement (SUP),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T15:20:05Z,,0,0,09000064805b962b
FDA-2017-H-6943-0001,FDA,FDA-2017-H-6943,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T14:32:29Z,,0,0,0900006482d75e99
FDA-2017-H-6934-0001,FDA,FDA-2017-H-6934,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T13:04:18Z,,0,0,0900006482d761ea
FDA-2017-V-4545-0003,FDA,FDA-2017-V-4545,Approval Letter from FDA CDRH to Foxconn Interconnect Technology,Other,Approval for Variance (VRA),2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T21:34:34Z,,0,0,0900006482d78a78
FDA-2017-H-6933-0001,FDA,FDA-2017-H-6933,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T12:56:12Z,,0,0,0900006482d75b25
FDA-2017-H-6939-0001,FDA,FDA-2017-H-6939,Complaint,Other,Complaint,2017-12-27T05:00:00Z,2017,12,2017-12-27T05:00:00Z,,2017-12-27T14:01:11Z,,0,0,0900006482d75d8e
FDA-1998-P-0262-0004,FDA,FDA-1998-P-0262,Internal Memo from FDA CVM to FDA DDM,Other,Memorandum,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,,2024-07-25T15:20:29Z,,0,0,0900006480a3e397
FDA-2015-D-1245-0020,FDA,FDA-2015-D-1245,Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System,Other,Guidance,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,,2024-11-07T01:16:09Z,,1,0,0900006482d734ba
FDA-2017-P-4249-0006,FDA,FDA-2017-P-4249,Withdrawal from GE Healthcare Inc,Other,Withdrawal,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,,2017-12-26T18:13:47Z,,0,0,0900006482d738a2